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In its purest form, gene therapy is
the delivery and expression of a
correct copy of a gene into cells in
which the endogenous gene is non-
functional. It can lead to cure — or
significant enhancement of the
quality of life — of the patient. The
concept is highly attractive as it
provides a therapeutic link between
laboratory-based studies on the
genetic basis of disease and attempts
to alleviate patient suffering.
In this context, a prototypic
disease for gene therapy is cystic
fibrosis (CF). Several years of genetic
analysis of affected patients led to
the cloning of the CFTR gene, which
contributes to a chloride ion
transport channel in epithelial cells,
and which is mutated in cystic
fibrosis patients. Expression of the
cloned, correct version of the gene in
cultured cells in which CFTR is
mutant corrects the pathological
phenotype, and replacement of
CFTR in only a proportion of
affected cells corrects the
physiological defect across the entire
epithelial cell sheet. To correct the
defect, expression of CFTR has
simply to be on rather than off, and
over-expression in cells which are not
the primary site of the disease
pathology does not seem to be
detrimental. All that remains,
therefore, is to translate these
experiments in cultured cells into
the context of a living patient — of
which more to come later.
Other monogenic diseases are
also candidates for treatment by gene
replacement therapies, including
Duchenne Muscular Dystrophy
(DMD) and the severe
immunodeficiency associated with
the lack of adenosine deaminase
(ADA). But not all monogenic
diseases are as simple, even in
theory, as these examples. For
instance, thalassemia is caused by
mutations in the genes which encode
haemoglobin, causing a deficiency of
functional α and β globin proteins
relative to one another. But
unregulated over-expression of, for
example, β globin may simply
convert a β thalassemia (relative lack
of functional β globin) into an
α thalassemia (relative lack of
functional α globin). In such cases,
regulated expression of the
therapeutic gene is required, either
quantitatively and/or temporally, to
achieve effective treatment.
If you can’t correct it, kill it
Increasingly, a range of different
approaches aimed at curing genetic
and acquired diseases are now falling
under the umbrella of gene therapy,
which make the definition as
epitomized by CF, DMD or even the
haemoglobinopathies difficult to
recognize. For example, therapeutic
genes may not be delivered to the
cell type that is itself affected:
human cells, engineered to express
and secrete high levels of Factor IX,
can be reimplanted in the body to act
as factories of secreted products to
treat haemophilia. But the most
dramatic variation on the gene
therapy theme comes from attempts
at treating cancer or acquired,
pathogen-related diseases such as
AIDS. In these cases, the classical
concept of gene therapy — the use
of genes to correct disease — has
been expanded to include the use of
genes with a license to kill.
Gene therapy against viral
diseases, such as targeting HIV in
AIDS patients, uses nucleic acid
sequences (anti-sense) with
specificity against viral transcripts, or
control sequences, so that the virus
can no longer complete its life cycle.
Similarly, gene therapy for cancer
represents a dramatic swing away
from the use of genes in a purely
‘restorative’ capacity. Populations of
malignant cells contain multiple
mutations, including both dominant
mutations in oncogenes and
recessive mutations in tumour
suppressor genes. Such a
multifactorial genetic disease could,
theoretically, be tackled by
conventional gene therapy;
functional copies of mutated tumour
suppressors (such as p53), or anti-
sense sequences against oncogenes,
could be delivered to cause the
tumour cells’ uncontrolled
proliferation to become more orderly,
invoking terminal differentiation or,
at best, cell death by apoptosis.
But the genetic complexity of
human tumours suggests that trying
to correct them genetically may be
much less effective than simply
trying to kill them. Various strategies
have been developed to achieve
this, including the delivery of
cytotoxic genes or genes which
activate the immune system to
recognize and kill tumour cells
spread throughout the body. The
preponderance of immunotherapy
protocols reflects two major
considerations. First, cancer is
usually fatal because it is a disease
of metastatic cells distributed
throughout the body. The
unrestricted access of immune cells
to all body areas makes them
attractive for recruitment to a
‘search and destroy’ capacity.
Second, without the response
amplification which an appropriately
activated immune system can
provide, there are currently no
vector systems that can deliver
enough toxic genes specifically to
sufficient numbers of tumour cells
to be effective. This latter point
highlights the key block to effective
gene therapy for just about any
disease — that of gene delivery.
Nice message – shame about the
messenger
The bottleneck into which all gene
therapy protocols eventually funnel is
that of gene delivery. Whatever
therapeutic gene is chosen, it must be
delivered to the cellular site of
activity. Where therapeutic strategies
allow, genes can be delivered to cells
removed from the patient, which are
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then transplanted in vivo (this
approach is used for cytokine-
modified anti-cancer vaccines or cell
factories for the production of
secretable proteins). But ex vivo cell
modification is expensive, laborious
and rarely appropriate. Hence, the
ultimate goal is to develop vectors for
direct in vivo delivery. This has
proved to be a considerable hurdle
and continues to be the main obstacle
hindering effective treatment of
disease using genetic therapy. 
Vectors must be safe, efficient
enough to transduce enough cells to
exceed the therapeutic threshold and
accurately targeted to reduce toxicity.
The most commonly used vectors
have been made from plasmid DNA
— usually complexed in some form
with liposomes to increase stability
— retroviruses and adenoviruses,
although others, such as adeno-
associated, herpes or vaccinia viruses
are increasingly coming into use.
Each type of vector has its own
advantages and drawbacks, which
weigh differently, depending on the
specific therapy required.
Thus, corrective gene therapy
requires long-term, stable gene
expression, ideally in the stem cell
population of the diseased tissue.
This requires a vector that integrates
into the genome (plasmid, retro- or
adeno-associated vectors), which
itself poses a potential mutagenic
risk. The non-integrating, rapidly
diluted vectors, such as adenoviruses,
would therefore be of limited value
(unless the target cells never divide),
although probably less mutagenic.
But the adenoviral vectors come into
their own in situations in which high
levels of transient gene expression
may suffice — for instance, in the
delivery of immunostimulatory or
cytotoxic genes to tumour cells,
which should not live long enough
for the lack of stable expression to be
a problem. The titres of these
adenoviral vectors (up to 1012
infectious units per ml) humble most
other systems.
Vectors must also be accurately
targeted to cell types in vivo. This
can be achieved at various levels of
sophistication. For example, topical
administration (intratumoral
injection for cancer, or airway lavage
for CF) allows them to be
concentrated at the site of action.
Further targeting can be achieved by
using natural tropisms of vectors, if
they exist, although relatively few
viruses infect specific cell types that
coincide with the target tissues used
by gene therapists. 
Considerable effort is now
dedicated to the molecular
engineering of viral and plasmid
vectors to restrict their tropisms to
specific cell types. Where expression
of a corrective gene is not toxic to
non-involved cells, this restriction
can be relatively loose (for example,
CFTR delivered to the airway
epithelial cells). By contrast, if a
cytotoxic gene is being delivered to
metastases in an organ of critical
value to the patient, tumour cell
targeting is essential. Molecular
modification of vector sequences has
already allowed recombinant viruses
to be targeted to specific cells using,
for example, transcriptional
targeting with tissue-specific
promoters and surface targeting by
altering the binding properties of
viral envelope proteins (Figure 1).
Once again, different vector systems
are differentially amenable to
targeting strategies but there is now
cause for genuine optimism that
recombinant vectors can be
effectively redirected to produce
targeted infection or expression.
Innovation for the future
There is clearly a great discrepancy
between what we want, and what we
can have, using the vectors currently
at our disposal. The attractive, but so
far elusive, perfect vector would
possess attributes from different
vector systems which would
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Figure 1
A vector targeted to at least two levels will
productively infect only target cells that are
compatible with both levels of targeting. The
vector shown displays an engineered ligand
(orange) that binds only to receptors known to
be expressed on the target cell surface (light
blue), and the therapeutic gene (green) is
expressed from a promoter–enhancer
combination that is activated by transcription
factors (red) present in the target cell. But
both cell-surface receptor and transcription
factor are also probably expressed individually,
but not in combination, in other non-target
cells. When the vector is delivered to the
target site, cells not expressing the receptor
((a) and (c)) will not be infected; cells
expressing the receptor will be infected ((b)
and (d)), but only cells expressing the receptor
and the appropriate transcription factors (d)
will also express the therapeutic gene
(productive infection). The number of levels of
targeting required to define absolute cell-type
specificity for a vector will depend upon the
target tissue type.
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themselves be tailored to the vector’s
clinical purpose. For example, gene
therapy of CF requires both the high
titre of adenoviruses and the long-
term integrating capacity of
retroviruses. Any vision for the future
must now include the development
of hybrid vectors that combine
properties of several systems to
produce designer vectors optimized
for different clinical situations.
In addition, manipulations of
vector structure or function often
reduce the already poor efficiencies
of the unmodified vector. With
target-cell populations of many
millions and vector systems with in
vitro titres of, at most, 1010–1011
infectious units per ml, the
magnitude of the gene delivery task
is already Herculean. But titres
determined in vitro on ordered
monolayers of readily exposed cells
rarely match what will realistically be
achieved in the patient. In vivo,
target cells may be hidden beneath
layers of other cells, embedded in a
tight tissue or tumour architecture, or
be below layers of mucus or other
physiological barriers. It is hardly
surprising, therefore, that virologists
are wistfully turning to the concept
of using viruses which have the
ability to replicate selectively in
target tissues. Here, a small vector
inoculum would initiate a spreading
infection which would be restricted
at the boundaries of the target tissue
by targeting features built into the
vector (Figure 2).
Although the thought of
replicating viruses often invokes
visions of Frankenstein, there is
both precedent and good scientific
rationale behind investigation of
such strategies. Indeed, it is
indisputable that our ability to
identify, clone and rebuild diseased
genes into potentially
therapeutically valuable
pharmaceuticals has greatly
outstripped our ability to package,
deliver and express these genes in
the appropriate cells of patients.
The challenge for the immediate
future is to manipulate targeting
features into vector systems, while
also modifying them to increase
viral titres. In this way, useful
numbers of cells will be safely,
accurately and efficiently
transduced. We should not be afraid
to look at radical innovations,
including the use of rigorously
designed and tested replicating or
hybrid vector systems, as these are
now required to translate gene
therapy beyond the sphere of virtual
treatments and into the real clinic.
Key references
Mulligan RC: The basic science of gene
therapy. Science 1993, 260:926-932.
Collins FS: Cystic fibrosis: molecular biology
and therapeutic implications. Science
1992, 256:774-779.
Dropulic B, Jeang KT: Gene therapy for human
immunodeficiency virus infection:
genetic antiviral strategies and targets
for intervention. Hum Gene Ther 1994,
5:927-939.
Roth JA, Cristiano R: Gene therapy for cancer:
what have we done and where are we
going? J Natl Cancer Inst 1997, 89:21-39.
Vile RG, Chong H: Immunotherapy:
combinatorial molecular immunotherapy
— a synthesis and suggestions. Cancer
Metastasis Rev 1996, 15:351-364.
Miller N, Vile RG: Targeted vectors for gene
therapy. FASEB J 1995, 9:190-199.
Verma I, Somia N: Gene therapy — promises,
problems and prospects. Nature 1997,
389:239-242.
Russell SJ: Replicating vectors for gene
therapy of cancer risks, limitations and
prospects. Eur J Cancer 1994, 30A:1165-
1171.
Address: Imperial Cancer Research Fund,
Laboratory of Molecular Therapy, ICRF
Oncology Unit, Imperial College School of
Medicine, Hammersmith Hospital, DuCane
Road, London, W12 0NN, UK.
E-mail:  r.vile@icrf.icnet.uk
Magazine R75
Figure 2
The advantages of using targeted replicating
vectors for gene therapy. (a) With the
recombinant vectors currently at our disposal,
delivery of viral vector stocks to the target
tissue will initiate a single round of infection
(green). Titres are generally low relative to the
numbers of target cells to be treated.
Therefore, with time, the only expansion of the
number of cells transduced with the
therapeutic gene will come from division of
cells infected at the first pass of the vector.
The initial infection will be restricted to target
cells because of the targeting features
incorporated into the vector. In many
physiological circumstances, vectors
currently have titres too low to transduce
enough target cells to obtain therapeutic
benefits. (b) If a stock of targeted, but
replicating, vector (blue) is delivered to the
target tissue at the same initial titre as the
recombinant vector in (a), the initial infection
will transduce the same number of target
cells. With time, however, the vector will
spread through the target tissue to infect a
large proportion of the cells (purple), such
that the threshold level of infected cells
required for therapeutic benefit will be
exceeded. Because of the targeted nature of
the vector, the spreading infection will cease
at the boundaries of the target tissue.
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